Dr. Brian Simmons, MD
Dermatology (Dermatology Physician)
18 Old Etna Rd
Lebanon, NH 03766
Who else practices at this address →
Grafton County includes mental health (62% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 1,209
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NH license 19094
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mary Hitchcock Memorial Hospital Lebanon, NH
- Cheshire Medical Center Keene, NH
- New London Hospital New London, NH
Medical groups
- Dartmouth-Hitchcock Clinic (1,472 clinicians)
- Mary Hitchcock Memorial Hospital (1,280 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,209
- Services billed
- 5,058
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,722 | 275 |
| Established patient office or other outpatient visit, 30-39 minutes | 527 | 369 |
| Established patient office or other outpatient visit, 20-29 minutes | 525 | 467 |
| Destruction of precancer skin growth, 1 growth | 456 | 358 |
| Biopsy of related skin growth, first growth | 286 | 247 |
| Destruction of skin growth, 1-14 growths | 284 | 239 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 104 | 75 |
| Biopsy of related skin growth, each additional growth | 104 | 65 |
| Destruction of precancer skin growth, 15 or more growths | 82 | 66 |
| Established patient office or other outpatient visit, 10-19 minutes | 78 | 76 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 7 payments worth $304 in total to this clinician.
| Biofrontera Inc. | $154 |
|---|---|
| Janssen Biotech, Inc. | $150 |
| Food and Beverage | $304 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $316,051 in research payments for these studies, mostly to the institutions running them.
- A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 52 weeks of treatment
Takeda Pharmaceuticals U.S.A., Inc. - TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require syst…
Boehringer Ingelheim Pharmaceuticals, Inc. - M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)
AbbVie Inc. - A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require syst…
Boehringer Ingelheim International GmbH - A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Argenx US, Inc. - A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company · Active, not recruiting · NCT05559359 - A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Eli Lilly and Company · Enrolling by invitation · NCT05735483
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.